Carboxypeptidases: Functions, Types, and Health Impact

Carboxypeptidases are enzymes that snip amino acids off the tail end of proteins and peptides. That sounds like a narrow job, but it turns out to be central to an enormous range of bodily functions: digesting food, activating hormones, regulating blood clots, tuning the immune system, and controlling blood pressure. Different carboxypeptidases handle each of these tasks, and when any of them malfunctions, the health consequences can be serious.

How They Clip Proteins Apart

All carboxypeptidases share the same basic goal: they recognize the free end of a peptide chain (the C-terminus) and remove the last amino acid. The details of how they do this depend on the type. Metallocarboxypeptidases, the best-studied group, rely on a zinc ion at their active site to activate a water molecule. That activated water attacks the bond holding the last amino acid in place, breaking it in a two-step process. The first step, where the water molecule strikes the peptide bond, is the slow one. Once that happens, the bond splits apart on its own.

Computational studies of carboxypeptidase A, the classic example, have mapped this reaction in detail. The zinc-bound water molecule is guided by a nearby glutamate residue that acts as a chemical helper, and the energy barrier for the rate-limiting first step comes to roughly 13 kilocalories per mole, which matches experimental measurements closely.¹ A separate computational approach confirmed that the highest energy hurdle involves transferring a proton to the departing amino group, after which the peptide bond breaks spontaneously.² The practical upshot: these enzymes are fast and efficient at their job, which is why they can handle the volume of protein processing the body demands.

Major Families and Where They Operate

Carboxypeptidases fall into two broad camps based on what drives their chemistry. Metallocarboxypeptidases use zinc (and occasionally other metals) and belong to the M14 family. Serine carboxypeptidases use a reactive serine residue instead. Within the metallocarboxypeptidase group alone, genomic studies have identified four subfamilies: M14A, M14B, M14C, and a more recently recognized group called M14D, which includes over a hundred members spread across bacteria, single-celled organisms, and animals.³ This is a much bigger enzyme family than researchers initially expected.

What makes the family even more varied is that individual members have very different preferences. Some only cleave amino acids with certain chemical properties: carboxypeptidase A prefers bulky or uncharged amino acids, while carboxypeptidase B targets positively charged ones. Others, like carboxypeptidase O, can handle both acidic and uncharged amino acids.⁴ These preferences determine where each enzyme works and what biological process it serves.

Breaking Down Food in the Gut

The most familiar role for carboxypeptidases is in digestion. After you eat, your pancreas releases a battery of enzymes into the small intestine. Endopeptidases like trypsin and chymotrypsin chop proteins into fragments by cutting internal bonds. Carboxypeptidases A and B then work on those fragments, trimming off amino acids from the exposed ends one at a time. Carboxypeptidase A handles fragments ending in bulky uncharged or aromatic amino acids, while carboxypeptidase B tackles fragments ending in positively charged residues like arginine and lysine.⁵ Together with the endopeptidases, they reduce dietary proteins to individual amino acids and very small peptides that the intestinal lining can absorb.

This teamwork also creates a practical problem for pharmaceutical developers trying to deliver protein-based drugs orally. The combination of endopeptidases and exopeptidases in the gut is thorough enough to destroy most therapeutic peptides before they can reach the bloodstream. That challenge has driven decades of research into protective coatings and delivery systems for oral peptide drugs.

Producing Hormones and Neuropeptides

Many hormones and signaling molecules in the brain start life as larger, inactive precursors called prohormones. To become active, these precursors need precise trimming. Carboxypeptidase E, discovered in 1982, plays a starring role in this process. After other enzymes cut a prohormone at internal sites, CPE removes the leftover basic amino acids from the new C-terminus, which is the final step in producing the active hormone or neuropeptide.⁶ CPE handles this job for a remarkably wide range of signaling molecules across both the endocrine system and the nervous system.

CPE also moonlights as a sorting receptor. A membrane-bound form of the enzyme helps direct prohormones into the right cellular compartments for regulated release. When CPE is missing, things go badly wrong. In mice carrying a mutation that knocks out CPE (called the Cpe-fat mutation), the pituitary prohormone pro-opiomelanocortin gets dumped out of cells in an uncontrolled way instead of being stored and released on cue. The result is a cascade of endocrine problems, including excess proinsulin in the blood and infertility.⁷

CPE’s involvement in producing neuropeptides has also drawn interest for psychiatric and metabolic conditions. Because CPE participates in making nearly every known neuropeptide, researchers have used it as a tool to discover new neuropeptides by identifying its substrates. Some of these newly found signaling molecules show promise as drug targets: small molecules acting on their receptors have reduced food intake and anxiety-like behavior in animal studies.⁸

Balancing Blood Clots and Clot Removal

When you form a blood clot to stop bleeding, your body also needs a way to dissolve that clot once the wound heals. The system that breaks down clots is called fibrinolysis, and a carboxypeptidase sits right at the crossroads between clotting and clot removal. Thrombin-activatable fibrinolysis inhibitor, or TAFI, circulates in the blood as an inactive precursor. When clotting ramps up and thrombin is generated, TAFI gets activated into an enzyme that slows clot breakdown.⁹

Activated TAFI works by trimming lysine residues off the surface of fibrin, the structural protein in clots. Those exposed lysines normally serve as landing pads for the enzymes that dissolve the clot. By removing them, TAFI effectively pulls the rug out from under the clot-dissolving machinery, slowing down the rate at which the clot is cleared.¹⁰ This bridging role between coagulation and fibrinolysis has made TAFI an attractive drug target. The idea is that blocking TAFI could help dissolve dangerous clots in conditions like stroke or deep vein thrombosis, and several pharmaceutical groups have pursued inhibitors.¹¹

Modulating the Immune Response

The same family of enzymes that regulates clotting also helps control inflammation. Two carboxypeptidases, CPN (carboxypeptidase N) and CPB2 (the same enzyme as TAFI, but viewed through its immune-related functions), both inactivate complement fragments C3a and C5a. These small proteins are powerful inflammatory signals: they recruit immune cells, increase blood vessel permeability, and amplify the immune response. Left unchecked, they cause tissue damage.

CPN circulates in the blood in an always-active form and handles the routine job of mopping up C3a and C5a generated during normal background immune activity. CPB2, by contrast, gets activated locally at sites where clotting and inflammation are intense, stepping in when the volume of inflammatory signals would overwhelm CPN’s capacity.¹² Studies in mice have confirmed that CPN is responsible for keeping system-wide levels of these complement fragments in check, while CPB2 acts as a local reinforcement.¹³ The division of labor is elegant: one enzyme patrols the whole body, the other deploys only where the action is.

Cancer Imaging and Targeted Therapy

One carboxypeptidase has become one of the most important targets in prostate cancer medicine. Prostate-specific membrane antigen, or PSMA, is actually glutamate carboxypeptidase II (GCPII), an enzyme that clips glutamate residues from certain substrates. PSMA is heavily expressed on prostate cancer cells and, strikingly, on the new blood vessels that grow to feed many types of solid tumors, including brain, breast, and bladder cancers.¹⁴

This expression pattern makes PSMA an outstanding handle for both finding and treating cancers. PSMA-targeted PET scans have transformed how doctors stage prostate cancer, and radioligand therapies that deliver radiation directly to PSMA-expressing cells are now approved treatments for advanced disease. The enzyme’s three-dimensional structure has been solved, providing a roadmap for designing inhibitors useful not only in cancer but also in neurological conditions where excess glutamate signaling causes damage.¹⁵ The fact that expression levels on prostate tumors correlate with cancer grade makes the enzyme useful for gauging how aggressive a cancer is, not just where it is located.

When Carboxypeptidase Genes Go Wrong

Mutations in carboxypeptidase genes can cause disease directly. The clearest example involves CPA1, the pancreatic digestive enzyme. A large genetic study found that people carrying variants of CPA1 that impair the enzyme’s function have a dramatically higher risk of early-onset chronic pancreatitis. In a German cohort, these defective variants appeared in about 3% of pancreatitis patients but only 0.1% of healthy controls, and the association was strongest in children diagnosed before age ten, where the odds ratio reached 84.⁵ The pattern replicated across European, Indian, and Japanese populations. Interestingly, the risk appears to come not from what the enzyme does but from what the misfolded protein does to the cells that make it: the faulty protein likely triggers stress in the cell’s protein-folding machinery.

A different kind of genetic defect involves cathepsin A, a serine carboxypeptidase found inside lysosomes. Cathepsin A has a dual life: it works as an enzyme, but it also acts as a structural bodyguard for two other lysosomal enzymes, beta-galactosidase and neuraminidase, protecting them from being chewed up inside the lysosome. When cathepsin A is missing or defective, both of those partner enzymes lose their stability. The result is galactosialidosis, a condition in which undigested sugars and lipids accumulate in cells throughout the body.¹⁶ Structural studies have confirmed that cathepsin A forms a physical complex with its partner enzymes and that this protective scaffolding role is separate from its enzymatic activity.¹⁷

Blood Pressure and Kidney Function

The system that controls blood pressure relies on a cascade of peptide signals, and carboxypeptidases show up at several points. The best-known player is ACE2, which converts angiotensin II (a potent blood-vessel constrictor) into angiotensin 1-7 (which has the opposite effect). But ACE2 is not the only enzyme that can do this. Prolylcarboxypeptidase, also called angiotensinase C, catalyzes the same conversion in the kidney, particularly in acidic environments where ACE2 is less effective. Studies in mice lacking prolylcarboxypeptidase showed that angiotensin 1-7 production dropped significantly at acidic pH, while remaining intact at neutral pH where ACE2 still functions.¹⁸

The existence of this backup pathway matters clinically. Many patients with kidney disease or metabolic conditions have impaired ACE2 activity. Knowing that prolylcarboxypeptidase can partially compensate opens the door to therapies that enhance this alternative route. Plasma levels of prolylcarboxypeptidase itself have also attracted interest as a biomarker: concentrations are elevated in people with obesity, diabetes, and chest pain, and they correlate with measures of artery thickening and cardiovascular risk factors like C-reactive protein.¹⁹

Rescuing Patients From Methotrexate Toxicity

One of the most dramatic medical uses of a carboxypeptidase involves glucarpidase, also known as carboxypeptidase G2. High-dose methotrexate is a mainstay of cancer treatment, especially for certain blood cancers and bone tumors. But the drug is cleared through the kidneys, and if kidney function falters during treatment, methotrexate levels can climb to dangerous and even lethal concentrations. Glucarpidase rapidly breaks methotrexate into inactive fragments through a non-kidney route, providing a lifeline when the kidneys cannot do the job.²⁰

Clinical data show that glucarpidase achieves a median 99% reduction in blood methotrexate levels within about 15 minutes of administration, and that reduction holds over the following 40 hours.²¹ The drug is FDA-approved specifically for this scenario. One limitation is that glucarpidase cannot cross cell membranes, so it only clears methotrexate from the bloodstream and does not reach the drug that has already entered cells. Researchers are exploring ways to deliver the enzyme intracellularly, but for now its benefit is confined to reducing circulating drug levels.²²

Lipid Droplets and Cellular Metabolism

Not every carboxypeptidase works on hormones, blood proteins, or dietary peptides. Carboxypeptidase O, the enzyme with unusually broad amino acid preferences mentioned earlier, has been found to associate with lipid droplets inside cells. When cells are given nutrient-rich conditions, CPO migrates to lipid droplets and increases their number. As nutrients deplete, CPO redistributes back to other cellular compartments and stops influencing lipid storage. Membrane cholesterol levels modulate this behavior: adding cholesterol to membranes pushes CPO away from lipid droplets and reduces its enzymatic activity.⁴ The functional significance of this is still being worked out, but it hints that some carboxypeptidases play roles in fat metabolism that go well beyond trimming peptides.

How the Family Grew So Large

Given how many different jobs carboxypeptidases perform, you might wonder how so many specialized versions evolved. Gene duplication is the short answer. A phylogenetic analysis of metallocarboxypeptidase genes across vertebrates revealed repeated duplication events, including some that appear to trace back to ancient whole-genome duplications in the fish lineage. The genes for AEBP1 and CPZ, for example, exist as pairs on separate chromosomes in ray-finned fish, surrounded by similar neighboring genes, a pattern consistent with large-scale chromosomal duplication.²³ CPO genes, by contrast, tend to sit in tandem clusters on the same chromosome, suggesting they arose from a different mechanism: unequal crossover during cell division, which accidentally copies a stretch of DNA.

Serine carboxypeptidase-like genes have diversified extensively in plants, too. In hickory (Carya cathayensis), researchers identified 44 members of the serine carboxypeptidase-like gene family, grouped into three major categories. One of these, CcSCPL4, turned out to promote the synthesis of EGCG, the antioxidant compound famously abundant in green tea. The same gene also enhanced drought tolerance when expressed in yeast and the model plant Arabidopsis.²⁴ These plant enzymes have diverged so far from their animal cousins that some no longer function as peptidases at all, instead catalyzing entirely different chemical reactions.

Industrial and Laboratory Uses

Carboxypeptidases have practical value outside the body as well. Because different carboxypeptidases chew through amino acids at different rates depending on the amino acid’s identity, biochemists have long used them as tools to figure out the sequence of amino acids at the end of an unknown protein. Two serine carboxypeptidases purified from the mold Aspergillus niger proved well-suited to this kind of sequencing work and also to synthesizing peptide bonds in the reverse direction, stitching amino acids together rather than pulling them apart.²⁵ That dual capability, both degrading and building peptide bonds depending on reaction conditions, has made fungal carboxypeptidases useful in the food industry and in pharmaceutical manufacturing where specific peptide sequences need to be constructed without the expense of purely chemical synthesis.